[The preventive effects of intraperitoneal injection of perfluorocarbon on acute lung injury in rat].
OBJECTIVE
To evaluate the preventive effects of intraperitoneal injection of perfluorocarbon (PFC) on acute lung injury (ALI) in rat.


METHODS
Sixty-three male Wistar rats were randomly divided into normal control (NC) group, lipopolysaccharide (LPS) group and C8F18 group. Rats in NC group were sacrificed 2 hours after anesthesia, and in LPS group and C8F18 group rats were either treated with normal saline or C8F18 15 ml/kg intraperitoneally 48 hours before LPS challenge. ALI was reproduced by intravenous injection of 7 ml/kg LPS, and the extent of lung injury was assessed by arterial partial pressure of oxygen (PaO(2)) level, histological examination, right lung wet weight/body weight (W/D) ratio, tumor necrosis factor-alpha (TNF-alpha) level in serum and broncho alveolar lavage fluid (BALF) at 2, 4, 6 hours after injury.


RESULTS
PaO(2) in LPS group and C8F18 group was significant lower than that in NC group (both P<0.05). There were no difference in PaO(2) between LPS group and C8F18 group at 2, 4, 6 hours after injury (all P>0.05). Compared with NC group, TNF-alpha level in blood and BALF increased obviously in LPS group and C8F18 group (both P<0.05). There was no significant change in content of TNF-alpha in C8F18 group BALF at 6 hours was significantly lower than that in LPS group (P<0.05).


CONCLUSIONS
Intraperitoneal administration of C8F18 (15 ml/kg) can not attenuate pathological changes or improve PaO(2) in rats with ALI induced by LPS in a short time.
Fan
Hao-Jun
HJ
General Hospital of Chinese People's Armed Police Forces, Beijing 100039, China. fanhaojun999@126.com
Liu
Shu-Ying
SY
Zhang
Jian-Peng
JP
Zhao
Xiao-Wei
XW
Gao
Hong-Mei
HM
Liu
You-Ning
YN
D055371:Acute Lung Injury / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D004195:Disease Models, Animal; D005466:Fluorocarbons / Q000008:administration & dosage* / Q000627:therapeutic use; D007274:Injections, Intraperitoneal; D008070:Lipopolysaccharides / Q000633:toxicity; D008168:Lung / Q000473:pathology; D008297:Male; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000378:metabolism
D005466:Fluorocarbons; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha